Holen Sie sich die Stockscreener-App
41.77
4.70%
-2.045
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Deep Track Capital, LP Trims Immunovant Inc (IMVT) Stake in Stra - GuruFocus
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *79wfgdDXy* - Villa de la Orotava
immunovant inc glp 1 receptor agonist diabetes weight managementView IiKNF3uia - Villa de la Orotava
Immunovant (IMVT) Results at a Glance: The Available Earnings Metric Delivers a Miss under the Current Snapshot; Post-Earnings: Shares Move Lower 1.98% in the Available RecordAnalyst Consensus Shift - vinanet.vn
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - Morningstar
Immunovant Inc GLP-1 Receptor Agonists Weight Management Diabetes Treatments *BI2Y6DHdO* - scchr.jp
Investigation launched into Immunovant officers for possible self-dealing harming shareholders - Pluang
Immunovant (IMVT) Stock: Moves 1.49% Up to $44.96 in Latest Trading; Immediate View: Support at $42.71 and Resistance at $47.21 Frame the Range in the Latest ReadingPassive Flow - vinanet.vn
Immunovant (IMVT) Q1 2027 Earnings Call Transcript - AOL.com
Immunovant (IMVT) Holds Steady at $41.82: Consolidation Between Key Support and ResistanceThematic ETF Flow - vinanet.vn
GSA Capital Partners LLP Takes $2.52 Million Position in Immunovant, Inc. $IMVT - MarketBeat
Assenagon Asset Management S.A. Has $639,000 Holdings in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT) Holds Steady at $41.82 as Shares Consolidate in a Tight RangeGamma Exposure - vinanet.vn
Dimensional Fund Advisors LP Sells 103,356 Shares of Immunovant, Inc. $IMVT - MarketBeat
Why Immunovant (IMVT) Is Up 5.2% After Wider Q1 Loss, Moderna Cash, And Pivotal Data Hype - simplywall.st
Immunovant (NASDAQ:IMVT) Reaches New 12-Month HighShould You Buy? - MarketBeat
Immunovant stock hits 52-week high at 41.37 USD By Investing.com - Investing.com Australia
Immunovant stock hits 52-week high at 41.37 USD - Investing.com
The Manufacturers Life Insurance Company Cuts Stock Position in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant, Inc. (IMVT) Stock Analysis: Assessing the 21% Potential Upside with Strong Analyst Confidence - DirectorsTalk Interviews
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Immunovant (IMVT) Pulls Back 2.26% as Biotech Jitters Persist — $37.04 Support in FocusRating Change - Vinanet
Liquidity Mapping Around (IMVT) Price Events - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Has $4.65 Million Stock Holdings in Immunovant, Inc. $IMVT - marketbeat.com
Immunovant Holds Near $40 as IMVT Consolidates Above Key SupportInverse ETF Flow - Vinanet
Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Renaissance Technologies LLC Invests $4.78 Million in Immunovant, Inc. $IMVT - MarketBeat
Immunovant Q1 2027 Earnings Call: Clinical Pipeline and Financial Outlook Take Center StageDividend Growth Analysis - vinanet.vn
Immunovant, Inc. Q1 2027 Earnings Call Summary - finance.yahoo.com
Immunovant Q1 Earnings Call Highlights - MarketBeat
Form 8K Immunovant Inc For: 6 August By Investing.com - Investing.com Nigeria
Immunovant, Inc. Stock 12‑Month Price Target Raised to $47.56, Implies 21% Upside - TradingView
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - The Globe and Mail
Immunovant Fiscal Q1 Loss Widens - marketscreener.com
Immunovant, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss - marketscreener.com
Immunovant, Inc. Q1 2027: Net loss $153.2M, EPS $(0.75) — 10-Q Summary - TradingView
Aug 06 (Reuters)Immunovant Q1 Operating Ex - Moomoo
Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026 - TradingView
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - manilatimes.net
Immunovant | 8-K: Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 - Moomoo
IMMUNOVANT Q1 NET INCOME USD -153.224 MILLION VS. IBES ESTIMATE USD -130.2 MILLION - Moomoo
Immunovant earnings up next as analysts eye pipeline pivot - Investing.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming DeadlineIMVT; HSACU; HSAC; and HSACW - TMX Newsfile
IMVT Maintained by JP Morgan -- Price Target Raised to $50.00 - GuruFocus
Immunovant (NASDAQ:IMVT) Price Target Raised to $50.00 - MarketBeat
Immunovant, Inc. (IMVT) Stock Analysis: Navigating a 21.72% Upside Potential in Biotech Investment - DirectorsTalk Interviews
Perceptive Advisors LLC Lowers Stake in Immunovant, Inc. $IMVT - MarketBeat
Immunovant (IMVT.US) will release its earnings report before the market opens on August 6. - moomoo.com
Why (IMVT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Immunovant (IMVT) Edges Lower as Shares Test Key Support LevelsPut Flow Alert - vinanet.vn
Immunovant, Inc. Revenue Breakdown – NASDAQ:IMVT - TradingView
Immunovant, Inc. (IMVT) Stock Analysis: Uncovering A Promising 18.57% Potential Upside - DirectorsTalk Interviews
Immunovant (IMVT) Tests Resistance at $41.37, Slight Pullback Signals CautionDealer Positioning - vinanet.vn
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy - Seeking Alpha
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 - marketscreener.com
Immunovant Inc (IMVT) Cash Flow - TradingKey
7.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):